Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global CAR T-cell therapy for multiple myeloma market was valued at USD 241 million in 2024 and is projected to reach USD 1.65 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 32.4% during the forecast period. This remarkable growth trajectory highlights the transformative potential of this innovative immunotherapy approach.
CAR T-cell therapy, formally known as chimeric antigen receptor T-cell therapy, represents a groundbreaking advancement in personalized medicine. This therapeutic approach involves genetically engineering a patient's own T-cells to express specific receptors that target cancer cell antigens. For multiple myeloma treatment, researchers primarily focus on B-cell maturation antigen (BCMA) as the target protein, though other targets like CD19 are also under investigation.
The market growth is driven by increasing prevalence of multiple myeloma (with approximately 176,000 new cases diagnosed globally each year), significant unmet medical needs in relapsed/refractory cases, and substantial investments in cell therapy research. While currently no CAR T-cell therapy holds full regulatory approval specifically for multiple myeloma, promising clinical trial results have accelerated development pipelines. Key players including Juno Therapeutics (a Bristol-Myers Squibb company) and Novartis AG are advancing late-stage clinical trials with encouraging response rates between 70-90% in some studies.
Increasing Prevalence of Multiple Myeloma
The global burden of multiple myeloma continues to rise, with approximately 176,000 new cases diagnosed annually worldwide. This increasing patient pool creates a growing demand for innovative treatment options like CAR T-cell therapy, particularly for relapsed/refractory cases.
Approval of Novel Therapies
The recent FDA approval of idecabtagene vicleucel (Abecma) in 2021 marked the first CAR T-cell therapy specifically for multiple myeloma, creating significant momentum in the market. Additional pipeline candidates in late-stage trials are expected to further drive growth.
The CAR T-cell therapy market for multiple myeloma is projected to grow at a CAGR of 42% from 2022-2028.
Improved clinical outcomes compared to traditional therapies are making CAR T-cell treatments increasingly attractive, with response rates exceeding 70% in some trials for heavily pretreated patients.
MARKET CHALLENGES
High Treatment Costs
CAR T-cell therapies carry price tags exceeding $400,000 per treatment, creating significant access barriers and reimbursement challenges. The complex manufacturing process contributes substantially to these costs.
Other Challenges
Manufacturing Complexity
Autologous CAR T-cell production requires sophisticated facilities and takes 3-4 weeks, limiting patient access and creating logistical challenges.
Toxicities Management
Cytokine release syndrome (CRS) and neurotoxicity remain significant concerns requiring specialized treatment centers and monitoring protocols.
Limited Treatment Centers
Only specialized centers currently have the infrastructure and expertise to administer CAR T-cell therapies, restricting patient access. There are fewer than 200 certified treatment centers currently operating in the United States.
Development of Allogeneic CAR-T Products
Off-the-shelf allogeneic CAR T-cell therapies in development could significantly reduce costs and manufacturing times while expanding patient access. Several candidates are currently in Phase II trials.
Expansion into Earlier Treatment Lines
Clinical trials are investigating CAR T-cell therapy in earlier lines of treatment, potentially expanding the eligible patient population by 3-5 times current levels.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Autologous CAR T-Cell Therapy currently dominates the market as it utilizes patients' own genetically modified cells, showing higher safety profiles and treatment efficacy. Allogeneic therapies are gaining research attention for their off-the-shelf potential but face immunological challenges that require further clinical validation. |
| By Application |
|
Relapsed/Refractory Cases represent the primary application area where CAR T-cell therapy demonstrates transformative outcomes. The high unmet need in this segment is driving strong clinical trial activity, with therapies showing remarkable response rates even in heavily pre-treated patients who exhausted other treatment options. |
| By End User |
|
Specialty Cancer Hospitals are the dominant end users due to the complex infrastructure requirements for CAR T-cell administration. These facilities have the necessary expertise in cellular therapy and can manage cytokine release syndrome and other severe adverse events associated with these treatments. |
| By Target Antigen |
|
BCMA-targeted Therapies lead this segment as BCMA is highly expressed on multiple myeloma cells. Recent clinical advancements demonstrate impressive efficacy of BCMA-directed CAR T-cells, making this the most well-validated target in multiple myeloma with multiple candidates in late-stage development. |
| By Therapy Stage |
|
Clinical Trials represent the most active segment as the market awaits first regulatory approvals. The pipeline is robust with therapies in Phase II/III trials showing deep responses and improved safety profiles. Commercialization is expected to accelerate as positive trial results accumulate and regulatory pathways become clearer. |
Innovative Therapies and Strategic Partnerships Drive Growth in CAR T-Cell Therapy Market
The CAR T-cell therapy market for multiple myeloma is dominated by biotechnology pioneers like Juno Therapeutics (acquired by Bristol-Myers Squibb) and Kite Pharma (Gilead subsidiary), who are leading clinical development efforts. Novartis remains a significant player with its CAR-T platform, while smaller biotechs like Legend Biotech and Bluebird Bio have emerged as formidable competitors through breakthrough designations.
Several pharmaceutical giants including Janssen (Johnson & Johnson) and Pfizer have entered strategic collaborations to advance CAR-T therapies. Specialized firms like Poseida Therapeutics and Cellectis focus on next-generation allogeneic approaches, while academic institutions contribute through technology licensing agreements with commercial partners.
List of Key CAR T-Cell Therapy for Multiple Myeloma Companies ProfiledLegend Biotech
Bluebird Bio
Pfizer
Cellectis
Poseida Therapeutics
Autolus Therapeutics
Cartesian Therapeutics
Allogene Therapeutics
Caribou Biosciences
Gracell Biotechnologies
Arcellx
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at $241 million in 2024 and is projected to reach $1,647 million by 2031, representing a remarkable 32.4% CAGR during the forecast period. This exponential growth is driven by the increasing prevalence of multiple myeloma, with approximately 35,000 new cases diagnosed annually in the U.S. alone.
Other TrendsPending Regulatory Approvals Driving Investment
While CAR T-cell therapy has shown promising clinical trial results for multiple myeloma, no therapies have received full regulatory approval yet. Several drug candidates are in Phase III trials, with key players like Juno Therapeutics and Kite Pharma actively pursuing FDA submissions. The anticipated approval of the first CAR T-cell therapy for multiple myeloma is expected to create significant market disruption.
Geographical Market ExpansionNorth America currently dominates the CAR T-Cell Therapy for Multiple Myeloma market, accounting for approximately 48% of global revenue. However, Asia-Pacific is projected to witness the highest growth (38.2% CAGR) driven by improving healthcare infrastructure and increasing investment in novel cancer therapies. Europe follows with strong growth projections as regulatory pathways for advanced therapies become more established.
Competitive Landscape Development
The market is characterized by strategic collaborations between biotech firms and pharmaceutical giants. Novartis recently acquired Collectis to strengthen its position in the CAR T-cell space. Currently, the top five companies control about 65% of the global market, though this share is expected to decrease as more competitors enter the space.
Therapeutic Segmentation PatternsCombination therapies are gaining traction, projected to grow at 34.1% CAGR compared to 29.8% for monotherapies. For refractory or relapsed multiple myeloma cases, which account for 72% of current applications, combination approaches incorporating CAR T-cells with immunomodulatory drugs show particular promise in clinical trials.
Regional Analysis: CAR T-Cell Therapy for Multiple Myeloma MarketEurope
Europe represents the second-largest market, with regulatory harmonization through EMA accelerating approvals. The region shows growing adoption despite budget constraints, with Germany and France leading utilization. Cost-effectiveness requirements drive innovative pricing models, while centralized treatment centers ensure quality control. Different reimbursement timelines across countries create staggered market penetration, with the UK often serving as the initial commercial launch country followed by DACH markets.
Asia-Pacific
The Asia-Pacific region exhibits the fastest growth, fueled by expanding healthcare access and rising myeloma prevalence. China dominates regional research activity, with biotech companies developing locally engineered CAR T products. Japan maintains rigorous safety standards but offers premium pricing, while Southeast Asian markets focus on cost-reduced innovations. Infrastructure limitations currently restrict treatment to major metropolitan areas across most markets.
South America
South America shows nascent but promising development, with Brazil and Argentina establishing regulatory frameworks for advanced therapies. Treatment remains concentrated at designated centers in major cities. Economic volatility impacts budget allocations, though some countries include CAR T in high-cost drug pools. Local clinical trial participation provides early access opportunities for eligible patients.
Middle East & Africa
The MEA region presents limited but strategic opportunities, with Gulf Cooperation Council countries leading adoption through specialized cancer centers. South Africa maintains the only established treatment program in sub-Saharan Africa. High costs restrict access predominantly to private insurance markets, though some governments are negotiating innovative funding mechanisms including outcome-based agreements.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global CAR T-cell therapy for multiple myeloma market was valued at USD 241 million in 2024 and is projected to reach USD 1.65 billion by 2031, exhibiting a CAGR of 32.4%.
Which key companies operate in Global CAR T-Cell Therapy for Multiple Myeloma Market?
-> Key players include Juno Therapeutics (Bristol-Myers Squibb), Kite Pharma, Novartis, and Cellectis, among others.
-> Key growth drivers include rising prevalence of multiple myeloma, unmet medical needs in relapsed/refractory cases, and substantial investments in cell therapy research.
-> North America currently holds a dominant market share, driven by advanced healthcare infrastructure and clinical trial activity, while Asia-Pacific is anticipated to witness significant growth.
-> Emerging trends include the focus on BCMA as a primary target antigen, advancement of combination therapies, and ongoing research into next-generation CAR T constructs to improve efficacy and safety.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates